Free Trial

HEALTHCARE: Bayer (BAYNGR: Baa2 neg/BBB/BBB): Bayer Summary

HEALTHCARE

The FT published a fairly high level summary of what's been going on at Bayer

  • Lack of revenue growth, stubborn debt levels, litigation costs
  • Positive catalysts can potentially be: Supreme Court victory in having FIFRA legislation applied to labelling requirements (overriding state level laws); a general improvement in efficiency and management, which Bill Anderson does seem highly focussed on; a few wins in the Pharma division to replace Xarelto.
  • Results are tomorrow

FT Link

70 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.

The FT published a fairly high level summary of what's been going on at Bayer

  • Lack of revenue growth, stubborn debt levels, litigation costs
  • Positive catalysts can potentially be: Supreme Court victory in having FIFRA legislation applied to labelling requirements (overriding state level laws); a general improvement in efficiency and management, which Bill Anderson does seem highly focussed on; a few wins in the Pharma division to replace Xarelto.
  • Results are tomorrow

FT Link